

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 4757503-00012 Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Fidaxomicin Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Kilsheelan
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 4 H302: Harmful if swallowed.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Warning

Hazard statements : H302 Harmful if swallowed.

Precautionary statements : **Prevention:**

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.

Hazardous components which must be listed on the label:

Fidaxomicin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Fidaxomicin	873857-62-6	Acute Tox. 4; H302	>= 50 - < 70
Sodium benzoate	532-32-1 208-534-8	Eye Irrit. 2; H319	>= 1 - < 10
Citric acid	77-92-9 201-069-1 607-750-00-3	Eye Irrit. 2; H319 STOT SE 3; H335	>= 1 - < 10

For explanation of abbreviations see section 16.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	: Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks	: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. Harmful if swallowed.
-------	--

4.3 Indication of any immediate medical attention and special treatment needed

Treatment	: Treat symptomatically and supportively.
-----------	---

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides
Chlorine compounds

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers	: Keep in properly labelled containers. Store in accordance with the particular national regulations.
Advice on common storage	: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s)	: No data available
-----------------	---------------------

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 4757503-00012 Date of last issue: 28.09.2024 Date of first issue: 15.08.2019

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Fidaxomicin	873857-62-6	TWA	200 µg/m ³ (OEB 2)	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Sodium benzoate	Workers	Inhalation	Long-term systemic effects	3 mg/m ³
	Workers	Inhalation	Long-term local effects	0,1 mg/m ³
	Workers	Skin contact	Long-term systemic effects	62,5 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	1,5 mg/m ³
	Consumers	Inhalation	Long-term local effects	0,06 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	31,25 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	16,6 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Citric acid	Fresh water	0,44 mg/l
	Marine water	0,044 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	34,6 mg/kg dry weight (d.w.)
	Marine sediment	3,46 mg/kg dry weight (d.w.)
	Soil	33,1 mg/kg dry weight (d.w.)
Sodium citrate	Fresh water	0,44 mg/l
	Marine water	0,044 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	34,6 mg/kg dry weight (d.w.)
	Marine water	3,46 mg/kg dry weight (d.w.)
	Soil	31,1 mg/kg dry weight (d.w.)
Sodium benzoate	Fresh water	0,13 mg/l
	Freshwater - intermittent	0,305 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

	Marine water	0,013 mg/l
	Sewage treatment plant	10 mg/l
	Fresh water sediment	1,76 mg/kg dry weight (d.w.)
	Marine sediment	0,176 mg/kg dry weight (d.w.)
	Soil	0,276 mg/kg dry weight (d.w.)
	Oral (Secondary Poisoning)	300 mg/kg food

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	
Material	: Chemical-resistant gloves
Skin and body protection	: Work uniform or laboratory coat.
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to NS EN 143
Filter type	: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	: granules
Colour	: White to light yellow
Odour	: No data available
Odour Threshold	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version 4.0	Revision Date: 14.04.2025	SDS Number: 4757503-00012	Date of last issue: 28.09.2024 Date of first issue: 15.08.2019
----------------	------------------------------	------------------------------	---

Flammability (liquids) : No data available

Upper explosion limit / Upper
flammability limit : No data available

Lower explosion limit / Lower
flammability limit : No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity
Viscosity, kinematic : Not applicable

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-
octanol/water : Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics
Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

Molecular weight : No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 4757503-00012 Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 875,04 mg/kg
Method: Calculation method

Components:

Fidaxomicin:

Acute oral toxicity : LD50 (Rat): > 1.000 mg/kg
LD50 (Dog): > 120 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 200 mg/kg
Application Route: Intravenous

Sodium benzoate:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version 4.0	Revision Date: 14.04.2025	SDS Number: 4757503-00012	Date of last issue: 28.09.2024 Date of first issue: 15.08.2019
----------------	------------------------------	------------------------------	---

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
Assessment: The substance or mixture has no acute oral toxicity

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg
Remarks: Based on data from similar materials

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5.400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Sodium benzoate:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Citric acid:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Sodium benzoate:

Species : Rabbit
Method : OECD Test Guideline 405
Result : Irritation to eyes, reversing within 21 days

Citric acid:

Species : Rabbit
Method : OECD Test Guideline 405
Result : Irritation to eyes, reversing within 21 days

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

Respiratory sensitisation

Not classified based on available information.

Components:

Sodium benzoate:

Test Type	:	Local lymph node assay (LLNA)
Exposure routes	:	Skin contact
Species	:	Mouse
Result	:	negative
Remarks	:	Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Fidaxomicin:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells Result: positive
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: Intravenous Result: negative
		Test Type: comet assay Species: Rat Result: negative

Sodium benzoate:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro Result: positive
Genotoxicity in vivo	:	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative

Citric acid:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019



Test Type: in vitro micronucleus test
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo

: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity

|| Not classified based on available information.

Components:

Sodium benzoate:

Species : Rat
Application Route : Ingestion
Exposure time : 24 month(s)
Result : negative

Reproductive toxicity

|| Not classified based on available information.

Components:

Fidaxomicin:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Intravenous injection
Fertility: NOAEL: 6,3 mg/kg body weight

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 12,6 mg/kg body weight
Remarks: No significant adverse effects were reported

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 7 mg/kg body weight
Remarks: No significant adverse effects were reported

Sodium benzoate:

Effects on fertility : Test Type: Four-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024
4.0 14.04.2025 4757503-00012 Date of first issue: 15.08.2019

Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

Citric acid-

Effects on foetal development : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure

Not classified based on available information

Components:

Citric acid-

Assessment : May cause respiratory irritation.

STOT - repeated exposure

Not classified based on available information

Repeated dose toxicity

Components:

Eidaxomicin-

Species	:	Rat
NOAEL	:	90 mg/kg
Application Route	:	Oral
Exposure time	:	28 D
Remarks	:	No significant adverse effects were reported

Species : Rat
NOAEL : 62,5 mg/kg
Application Route : Intravenous
Exposure time : 14 D

Species	:	Dog
NOAEL	:	9.600 mg/kg
Application Route	:	Oral
Exposure time	:	3 M
Symptoms	:	Vomiting
Remarks	:	No significant adverse effects were reported

Species	:	Monkey
NOAEL	:	90 mg/kg
Application Route	:	Oral
Exposure time	:	28 D
Remarks	:	No significant adverse effects were reported

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 4757503-00012 Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

Species	:	Juvenile rat
NOAEL	:	200 mg/kg
Application Route	:	Oral
Exposure time	:	28 D
Remarks	:	No significant adverse effects were reported

Sodium benzoate:

Species	:	Rat
NOAEL	:	1.000 mg/kg
Application Route	:	Ingestion
Exposure time	:	24 Months

Citric acid:

Species	:	Rat
NOAEL	:	4.000 mg/kg
LOAEL	:	8.000 mg/kg
Application Route	:	Ingestion
Exposure time	:	10 Days

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Fidaxomicin:

Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, constipation

SECTION 12: Ecological information

12.1 Toxicity

Components:

Fidaxomicin:

Toxicity to algae/aquatic plants : EC50 (Anabaena flos-aquae (cyanobacterium)): > 18,4 mg/l
Exposure time: 72 h

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

		Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
		NOEC (Anabaena flos-aquae (cyanobacterium)): 5,8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	:	EC50 : > 50 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC : 5,9 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic toxicity)	:	NOEC: 8,91 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 19,6 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211
Sodium benzoate:		
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 484 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 96 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 32 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

Citric acid:

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 1.535 mg/l Exposure time: 24 h

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

||

12.2 Persistence and degradability

Components:

Sodium benzoate:

||| Biodegradability : Result: Readily biodegradable.
||| Biodegradation: 75 %
||| Exposure time: 28 d

Citric acid:

||| Biodegradability : Result: Readily biodegradable.
||| Biodegradation: 97 %
||| Exposure time: 28 d
||| Method: OECD Test Guideline 301B

12.3 Bioaccumulative potential

Components:

Fidaxomicin:

||| Partition coefficient: n-octanol/water : log Pow: 4,4

Sodium benzoate:

||| Partition coefficient: n-octanol/water : log Pow: 1,88

Citric acid:

||| Partition coefficient: n-octanol/water : log Pow: -1,72

12.4 Mobility in soil

Components:

Fidaxomicin:

||| Distribution among environmental compartments : log Koc: 0,80

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.2 UN proper shipping name

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version 4.0	Revision Date: 14.04.2025	SDS Number: 4757503-00012	Date of last issue: 28.09.2024 Date of first issue: 15.08.2019
----------------	------------------------------	------------------------------	---

14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks	:	Not applicable for product as supplied.
---------	---	---

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

:

Conditions of restriction for the following entries should be considered: Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).
REACH - List of substances subject to authorisation (Annex XIV)
Regulation (EU) No 2024/590 on substances that deplete the ozone layer
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)
Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals

:

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.
H319 : Causes serious eye irritation.
H335 : May cause respiratory irritation.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Eye Irrit. : Eye irritation
STOT SE : Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECA - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
4757503-00012

Date of last issue: 28.09.2024
Date of first issue: 15.08.2019

of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Acute Tox. 4

H302

Classification procedure:

Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN